Drugs / C-11 PiB
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01723553 | Nov 2012 → Mar 2015 | Alzheimer disease, logopenic progressive aphasia, posterior cortical atrophy | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01609335 | Jul 2012 → Aug 2013 | Alzheimer disease | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01623284 | Mar 2010 → Jan 2015 | aphasia, apraxia, semantic dementia | Mayo Clinic | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03503331 | Apr 2018 → Oct 2028 expected | Alzheimer disease | University of Alabama at Birmingham | Recruiting | No outcome recorded |
| Phase 2 | NCT01607476 | Jul 2012 → Dec 2014 | Alzheimer disease | Mayo Clinic | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [C-11]PiB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03503331 ↗ |
| Known as | Pittsburgh compound B | “F-18 FDG and C-11 Pittsburgh compound B (PiB) are two drugs used in PET scans.” NCT01609335 ↗ |
| Modality | Diagnostic / imaging agent | “F-18 FDG and C-11 Pittsburgh compound B (PiB) are two drugs used in PET scans.” NCT01609335 ↗ |
| Route | Intravenous | “One time intravenous administration of 8-22 millicurie (mCi) C11 PiB” NCT01607476 ↗ |